Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Dynavax Technologies Corp. (NASDAQ: DVAX).

Full DD Report for DVAX

You must become a subscriber to view this report.


Recent News from (NASDAQ: DVAX)

Novavax: A Break In The Action
Buy The Decline Novavax ( NVAX ) is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company recently reported quarter 3 earnings earlier this month missing on revenue by $1.89 ...
Source: SeekingAlpha
Date: December, 03 2018 03:58
Biotech Analysis Central Pharma News: Johnson & Johnson's Partnership, Dynavax's Advancements, Aveo's Positive Results
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Johnson & Johnson Acquires Rights To A Drug That Treats Rare Forms Of Cancer News: Recently, Johnson & Johnson ( JNJ ) announced that it had ...
Source: SeekingAlpha
Date: November, 07 2018 16:20
Dynavax Approaches The Critical Inflection Point
At first glance, the Q3 2018 earnings release from Dynavax Technologies (DVAX) did not look so hot. The company missed on both revenues and earnings , with the meager revenue growth over Q2 looking especially worrisome. Heplisav-B, Dynavax’s best-in-class Hepatitis B vaccine, began i...
Source: SeekingAlpha
Date: November, 07 2018 01:00
Dynavax Technologies - Q3 Review, Liquidity, And The Debt Agreement
Dynavax Technologies ( DVAX ) equity value has been in a slow steady decline over the last twelve months as the rollout of the Heplisav-B hepatitis vaccine has been slower than hoped. This latest quarter was not encouraging, and next quarter looks to be much of the same. DVAX has a promising...
Source: SeekingAlpha
Date: November, 06 2018 16:55
Dynavax up 7% premarket after Q3 report
Dynavax Technologies (NASDAQ: DVAX ) is up  7%  premarket on light volume following its Q3 report that included $1.5M in sales for hepatitis B vaccine Heplisav-B. More news on: Dynavax Technologies Corporation, Healthcare stocks news, Stocks on the move, Earnings news and comme...
Source: SeekingAlpha
Date: November, 06 2018 09:15
Dynavax Technologies Corporation (DVAX) CEO Eddie Gray on Q3 2018 Results - Earnings Call Transcript
Dynavax Technologies Corporation (DVAX) Q3 2018 Earnings Conference Call November 5, 2018 4:30 PM ET Executives Ryan Spencer - Vice President of Corporate Strategy and Communications Eddie Gray - Chief Executive Officer Robert Janssen - Chief Medical Officer Michael Ostrach - S...
Source: SeekingAlpha
Date: November, 05 2018 22:15
Dynavax misses by $0.08, misses on revenue
Dynavax (NASDAQ: DVAX ): Q3 GAAP EPS of -$0.65 misses by $0.08 . Revenue of $1.46M misses by $1.71M . Cash and equivalents of $180.2M. Press Release More news on: Dynavax Technologies Corporation, Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: November, 05 2018 16:03
Dynavax Reports Third Quarter 2018 Financial Results, Progress on HEPLISAV-B Launch, and Updated SD-101 Data in Three Patient Populations
Conference Call to be held Today at 4:30pm ET/1:30pm PT BERKELEY, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2018 along with an update on the launch progress of HE...
Source: GlobeNewswire
Date: November, 05 2018 16:01
Notable earnings after Monday's close
ACHC , AEL , AKCA , ANDE , APLE , APTS , ATRO , ATUS , AVD , AWR , BE , BHF , BKD , BKH , BKNG , CAR , CBT , CDEV , COHU , CRZO , CTRE , CXW , DCO , DCP , DRH , DVAX , ELF , EVBG , FMC , FN , FNV , FRGI , FRPT , FTDR , HHC , IFF , INSY , IPAR , ITRI , ...
Source: SeekingAlpha
Date: November, 04 2018 17:35
Dynavax's Melanoma Results May Be The Next Step To Its Evolution
Recently, Dynavax Technology Corporation ( DVAX ) announced positive results from its Phase 1b/2 study treating patients with advanced melanoma. The results were encouraging because they stayed the same despite the addition of more patients into the study. On top of that, patients being ...
Source: SeekingAlpha
Date: October, 29 2018 13:09

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1710.5210.1510.7110.07872,582
2018-12-1410.3910.6210.9810.39759,367
2018-12-1311.6210.4911.6410.401,474,648
2018-12-1210.9811.6411.6810.84814,847
2018-12-1111.0010.8211.0110.62406,819

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1769,282163,57942.3538Short
2018-12-1491,614217,68042.0865Short
2018-12-13195,950475,62041.1989Short
2018-12-1263,379217,08629.1953Cover
2018-12-1144,944110,34240.7315Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DVAX.


About Dynavax Technologies Corp. (NASDAQ: DVAX)

Logo for Dynavax Technologies Corp. (NASDAQ: DVAX)

Not available

 

Contact Information

 

 

Current Management

  • Dino Dina / President, CEO
  • William J. Dawson / CFO

Current Share Structure

  • Market Cap: $1,165,771,221 - 05/15/2018
  • Issue and Outstanding: 61,681,017 - 03/01/2018

 


Recent Filings from (NASDAQ: DVAX)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 18 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 16 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 22 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 22 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 22 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 22 2018

 

 


Daily Technical Chart for (NASDAQ: DVAX)

Daily Technical Chart for (NASDAQ: DVAX)


Stay tuned for daily updates and more on (NASDAQ: DVAX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: DVAX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DVAX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of DVAX and does not buy, sell, or trade any shares of DVAX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/